Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 6676967
SERIAL NO

08962422

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Methods for reducing flushing in individuals being treated for hyperlipidemia with nicotinic acid are disclosed. According to the methods of the present invention, flushing can be reduced in individuals under going nicotinic acid therapy without causing drug-induced hepatotoxicity to a level that would require the nicotinic acid therapy to be discontinued by orally administering to the individuals intermediate nicotinic acid formualtions having unique biopharmaceutical characteristics as a single dose once per day. While the methods of the present invention contemplate administering the intermediate release nicotinic acid formulations at any time during a 24 hour period, it is preferable to administer them once-a-day as a single dose during the evening or at night between about 6:00 pm. and 12:00 a.m., preferably between about 8:00 p.m. and 12:00 a.m., and most preferably between about 8:00 p.m. and 10:00 p.m.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ABBOTT LABORATORIESABBOTT PARK, IL, US538
ABBOTT RESPIRATORY LLCABBOTT PARK, IL3

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bova, David J Boca Raton, FL 29 66
Cefali, Eugenio A Fort Lauderdale, FL 14 128

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (11)
4272548 Process for the lowering of increased levels of cholesterol and neutral fat in the blood of humans 19 1980
4268524 Method of treating abnormal lipoprotein ratios with acylcarnitine 12 1980
4455298 Pharmaceutical preparations with gastro-protective action 16 1982
4680323 Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration 37 1983
4764374 Pharmaceutical composition based on guar gum and other antacids for protection of the oesogastroduodenal mucous membrane 13 1986
4775535 Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics 22 1986
4882167 Dry direct compression compositions for controlled release dosage forms 74 1987
4855143 Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics 22 1988
4920123 Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals 15 1988
5110817 Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals 11 1990
5145678 Method of reducing blood serum cholesterol 13 1991
 
SYNTEX (U.S.A.) INC. (3)
4452775 Cholesterol matrix delivery system for sustained release of macromolecules 196 1982
4571333 Controlled release naproxen and naproxen sodium tablets 51 1983
4803079 Controlled release naproxen and naproxen sodium tablets 51 1985
 
Verex Laboratories, Inc. (4)
4375468 Constant order release aspirin composition and method of treating arthritis 34 1982
4461759 Constant release rate solid oral dosage formulations of veropamil 39 1983
4522804 Constant release rate solid oral dosage formulations of propranolol 13 1984
4525345 Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions 29 1984
 
TERUMO KABUSHIKI KAISHA (1)
4794115 Method of treating hyperlipemia 14 1986
 
HAUSER-KUHRTS, INC. (2)
5023245 Improved niacin formulation 30 1989
5096714 Prolonged release drug tablet formulations 38 1989
 
MITSUBISHI PETROCHEMICAL CO., LTD. (1)
4777042 Cholesterol level-lowering agents 23 1987
 
Eli Lilly and Company (1)
4968508 Sustained release matrix 88 1989
 
HOECHST AKTIENGESELLSCHAFT (2)
4792554 Pyridine compounds, pharaceutical compositions, their use in allergy therapy 9 1986
4935246 Process for the coating of granules 126 1988
 
ELAN PHARMA INTERNATIONAL LIMITED (5)
4940588 Controlled release powder and process for its preparation 178 1988
4952402 Controlled release powder and process for its preparation 240 1988
5015479 Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine 43 1988
4973469 Drug delivery system 66 1989
5128142 Sustained release drug delivery system 52 1989
 
CLEAR LAKE DEVELOPMENT GROUP, 201 N. MAIN, WICHITA, KN., 67202 A PARTNERSHIP (1)
4457907 Composition and method for protecting a therapeutic drug 107 1982
 
EVREKA, INC. (1)
4362711 Blood cholesterol level reducing agent and method 24 1980
 
MERCK SHARP & DOHME CORP. (1)
5314697 Stable extended release oral dosage composition comprising loratadine and pseudoephedrine 38 1992
 
FARVALSA A.G. (1)
4837032 Theophylline sustained release tablet 18 1986
 
MEMORIAL UNIVERSITY OF NEWFOUNDLAND (1)
4775483 Method to reduce plasma cholesterol 37 1986
 
MOUNT SINAI SCHOOL OF MEDICINE (1)
4279898 In vivo inhibitors of cholesterol biosynthesis 6 1980
 
WARNER-LAMBERT COMPANY (7)
4747881 Ingestible aggregate and delivery system prepared therefrom 111 1985
4814354 Lipid regulating agents 33 1986
4851233 Sustained release formulations 13 1986
4789549 Sustained release dosage forms 33 1987
4950689 Pectin delivery system 20 1987
5030653 Antihyperlipidemic and antiatherosclerotic compounds and compositions 15 1990
5167964 Semi-enteric drug delivery systems and methods for preparing same 94 1992
 
FIRST NATIONAL BANK OF GRAPEVINE (1)
5002774 Sustained release pharmaceutical tablet 39 1989
 
MERCK & CO., INC. (10)
4795644 Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins 62 1987
4814183 Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins 55 1987
4997658 Method for enhancing the lowering of plasma cholesterol levels 13 1988
5049696 Antihypercholesterolemic compounds 8 1989
5009895 Sustained release with high and low viscosity HPMC 33 1990
5010105 Antihypercholesterolemic compounds 8 1990
5182298 Cholesterol lowering agents 21 1991
5262435 Cholesterol lowering compounds 21 1992
5258401 Cholesterol lowering compounds 10 1992
5256689 Cholesterol lowering compounds 17 1992
 
NISSHIN SEIFUN GROUP INC. (1)
5025012 Nicotinic acid derivatives and pharmaceutical compositions comprising same 39 1990
 
NESTEC S.A. (1)
4999380 Treatment of lipoprotein disorders associated with cholesterol metabolism 9 1988
 
ADD ADVANCED DRUG DELIVERY TECHNOLOGIES AG (1)
4992278 Therapeutic system for sparingly soluble active ingredients 38 1989
 
BASF CORPORATION (2)
4605666 Process for preparing spray-dried powders containing a water-soluble vitamin and powders prepared thereby 16 1984
4830859 Process for lubricating water-soluble vitamin powders 12 1987
 
EURAND INTERNATIONAL S.P.A. (2)
4812316 Process for the preparation of stabilized isosorbide-5-mononitrate tablets, being also of sustained release, and formulations thus obtained 12 1986
5047248 Formulation for preparing sustained release drugs for oral administration 31 1989
 
AMERICAN HOME PRODUCTS CORPORATION (2)
4309404 Sustained release pharmaceutical compositions 71 1981
5190940 Cholesterol ester hydrolase inhibitors 6 1991
 
ALFA WASSERMANN S.P.A. (1)
4888178 Galenic formulations with programmed release containing naproxen 44 1989
 
TEIJIN LIMITED (2)
4755544 Sustained release preparation 55 1986
4729895 Composition for solid pharmaceutical preparations of active vitamins D.sub.3 31 1987
 
PURDUE PHARMA L.P. (2)
4828836 Controlled release pharmaceutical composition 222 1987
4834985 Controlled release pharmaceutical composition 234 1987
 
Aktiebolaget Hassle (2)
4803081 New pharmaceutical preparations with extended release 38 1987
4942040 Pharmaceutical preparation and a process for its preparation 39 1988
 
PAUL ROYALTY FUND, L.P. (1)
4839177 System for the controlled-rate release of active substances 135 1986
 
RHONE-POULENC RORER PHARMACEUTICALS INC. (1)
4994267 Transdermal acrylic multipolymer drug delivery system 100 1989
 
DRUGTECH CORPORATION (1)
5133974 Extended release pharmaceutical formulations 312 1990
 
CARDINAL ASSOCIATES, INC. DBA BERGSTROM NUTRITION (1)
4568547 Solid pharmaceutical compositions comprising MSM and their production 40 1984
 
Buhk Meditec A/A (1)
5213808 Controlled release article with pulsatile release 185 1990
 
E. R. Squibb & Sons, Inc. (8)
4505890 Controlled release formulation and method 23 1983
4610870 Controlled release formulation 107 1984
4756911 Controlled release formulation 101 1986
4792452 Controlled release formulation 111 1987
5130333 Method for treating type II diabetes employing a cholesterol lowering drug 50 1990
5169638 Buoyant controlled release powder formulation 121 1991
5190970 Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor 34 1991
5260305 Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination 34 1992
 
MERZ + CO. GMBH & CO. (2)
RE32581 Certain substituted phenyl esters of nicotinic acid, compositions and methods of using same for treatment of hyperlipidemia 14 1984
4758581 Pyridyl N-oxides 6 1987
 
Zumbro Enterprises, Inc. (1)
4696762 Hydroxypropylmethylcellulose 17 1985
 
VIRGINIA COMMONWEALTH UNIVERSITY OF RICHMOND, VA (1)
4920115 Method of lowering LDL cholesterol in blood 36 1988
 
SINNREICH TECHNOLOGIEN GMBH (1)
4996058 Covered retard forms 118 1988
 
Boehringer Ingelheim GmbH (1)
4361546 Retard form of pharmaceuticals with insoluble porous diffusion coatings 36 1981
 
NORTH CAROLINA CENTRAL UNIVERSITY (NCCU) (2)
5034528 Compositions for the control of hyperlipidemia 7 1988
4946963 Compounds for the control of hyperlipidemia using N-substituted isoxazolidine-3,5-diones 6 1988
 
Boehringer Ingelheim KG (1)
4547359 Divisible pharmaceutical tablet with delayed active ingredient release 19 1984
 
WYETH (1)
4966768 Sustained release etodolac 29 1988
 
HERCULES INCORPORATED (1)
4759923 Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives 109 1987
 
GIST-BROCADES N.V. (1)
5211958 Pharmaceutical composition and process for its preparation 22 1992
 
PEDINOL PHARMACAL INC. (1)
4753801 Sustained release tablets 50 1985
 
BASF AKTIENGESELLSCHAFT (1)
4925905 Preparation of water-soluble copolymers based on monoethylenically unsaturated carboxylic acids 11 1989
 
TCF NATIONAL BANK (2)
5126145 Controlled release tablet containing water soluble medicament 129 1990
* 5268181 Method of using niacin to control nocturnal cholesterol synthesis 19 1992
 
LOTTE CO., LTD. (1)
5171570 Substance having suppressing function for diseases relating to increase in cholesterol, and foods and drinks in which it is used 15 1990
 
NOVARTIS CORPORATION (1)
4857336 Oral therapeutic system having systemic action 44 1987
 
HITACHI MAXELL, LTD. (1)
4695910 Recording disc cartridge having an improved hub assembly 21 1984
 
ROUSSEL UCLAF (2)
4432966 Compressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating 87 1982
4478819 Novel oral preparations 41 1983
 
NORWICH EATON PHARMACEUTICALS, INC. (1)
5032406 Dual-action tablet 44 1989
 
LIPOGENICS, INC. (1)
4603142 Cholesterol lowering method of use 53 1984
 
FUJISAWA PHARMACEUTICAL CO., LTD. (2)
4428951 Long acting pharmaceutical composition 7 1982
4695467 Sustained release tablet 57 1985
 
The University of North Carolina at Chapel Hill (1)
4866058 Method for control of hyperlipidemia 11 1988
 
Bio-Dar Ltd (1)
4749575 Microencapsulated medicament in sweet matrix 155 1986
 
CIBA-GEIGY CORPORATION (1)
4353887 Divisible tablet having controlled and delayed release of the active substance 58 1980
 
BANNER PHARMACAPS INC. (2)
4708834 Preparation of gelatin-encapsulated controlled release composition 127 1986
4795642 Gelatin-encapsulated controlled-release composition 59 1987
 
DEGUSSA-HULS AKTIENGESELLSCHAFT (1)
4959478 Method of producing-coarse crystalline nicotinic acid with a high degree of purity 7 1989
 
INTERFERON SCIENCES, INC. (1)
4744907 Blood cell separation 7 1987
 
NIKKEN CHEMICALS CO., LTD. (2)
4261970 Theophylline sustained release granule 21 1980
4692337 Sustained release pharmaceutical tablet of theophylline and production process thereof 29 1984
 
BRISTOL-MYERS SQUIBB COMPANY (2)
5011947 Antihypercholesterolemic alkylene compounds 10 1990
5110940 Antihypercholesterolemic tetrazole compounds 6 1991
 
RHODIA INC. (1)
4710519 Process for preparing spray dried acetaminophen powder and the powder prepared thereby 21 1985
 
ROQUETTE FRERES (1)
5264226 Process for preparing dairy products with a low content of sterols, particularly of cholesterol 17 1991
 
BAYER HEALTHCARE AG (1)
4892741 Press coated DHP tablets 77 1988
 
The Procter & Gamble Company (1)
5116610 Compositions for treating hypercholesterolemia 23 1991
 
FOREST LABORATORIES, INC. (7)
4357469 Carrier base material for prolonged release therapeutic compositions 40 1981
4369172 Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose 242 1981
4389393 Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose 314 1982
4795327 Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants 44 1984
4540566 Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose 72 1984
4849229 Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants 30 1988
4983398 Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates 33 1988
 
REXALL SHOWCASE INTERNATIONAL, INC. (1)
4824672 Method and composition for reducing serum cholesterol 50 1986
 
AMERICAN CYANAMID COMPANY (2)
4485105 Method of treating hyperlipidemia with 4-(monoalkylamino)benzoic acid amides 25 1980
4440940 Anti-atherosclerotic agents 21 1981
 
Key Pharmaceuticals, Inc. (1)
4556678 Sustained release propranolol tablet 47 1982
 
ZYMA SA (1)
4784858 Controlled release tablet 61 1986
 
PHARMACIA & UPJOHN COMPANY (1)
4824677 Grooved tablet for fractional dosing of sustained release medication 33 1986
 
REID-ROWELL, INC., 640 TENTH STREET, ATLANTA, GEORGIA 30318, A GEORGIACORP. (2)
4539198 Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range 53 1983
4690824 Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range 16 1985
 
ALZA CORPORATION (6)
4326525 Osmotic device that improves delivery properties of agent in situ 147 1980
4576604 Osmotic system with instant drug availability 106 1983
4673405 Osmotic system with instant drug availability 73 1986
4871548 Controlled release dosage form comprising different cellulose ethers 79 1987
4851232 Drug delivery system with means for obtaining desirable in vivo release rate pattern 51 1987
4915952 Composition comprising drug, HPC, HPMC and PEO 23 1989
 
PENWEST PHARMACEUTICALS CO. (2)
4994276 Directly compressible sustained release excipient 71 1988
5169639 Controlled release verapamil tablets 34 1991
 
EURO-CELTIQUE S.A. (2)
4844907 Pharmaceutical composition comprising analgesic and anti-inflammatory agent 154 1986
4834965 Controlled release pharmaceutical composition 112 1987
 
SCHERING CORPORATION (6)
4282233 Antihistaminic 11-(4-piperidylidene)-5H-benzo-[5,6]-cyclohepta-[1,2-b]-pyridines 103 1980
4695591 Controlled release dosage forms comprising hydroxypropylmethylcellulose 49 1985
4657757 Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate 14 1985
4990535 Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine 57 1989
5100675 Sustained release tablet comprising loratadine, ibuprofen and pseudoephedrine 56 1990
5262165 Transdermal nitroglycerin patch with penetration enhancers 29 1992
 
KNOLL PHARMACEUTICAL COMPANY (1)
4308251 Controlled release formulations of orally-active medicaments 54 1980
 
Dr. Karl Thomae GmbH (2)
4367217 Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof 55 1980
5286736 Pyridyl compounds and pharmaceutical compositions containing these compounds 12 1993
 
Zyna SA (1)
4886669 Galenical formulation 60 1987
 
ALRA LABORATORIES, INC., GURNEE, ILLINOIS (1)
4684516 Sustained release tablets and method of making same 52 1985
 
DOW CHEMICAL COMPANY, THE (4)
4678516 Sustained release dosage form based on highly plasticized cellulose ether gels 63 1984
4734285 Sustained release compositions 39 1985
4704285 Sustained release compositions comprising hydroxypropyl cellulose ethers 65 1985
5039341 Binder composition comprises a blend of a high viscosity and low viscosity hydroxypropyl methylcellulose ether, and a tape joint composition containing such binder 20 1989
 
MITSUI TOATSU CHEMICALS, INC. (1)
4713245 Granule containing physiologically-active substance, method for preparing same and use thereof 47 1985
 
Unimed, Inc. (1)
4291030 Method of lowering blood cholesterol 9 1980
 
PIERRE FABRE MEDICAMENT (1)
5132116 Tablets of the hydrophilic matrix type based on salbutamol and a process for their preparation 32 1991
 
NISSAN CHEMICAL INDUSTRIES, LTD. (1)
4624950 Method for treating atherosclerosis hyperlipidema, lipid deposition on arterial walls, or raising the ratio of high density lipoprotein cholesterol to total cholesterol in serum 7 1984
 
NATIONAL BIOSOURCE, INC., 1187 COAST VILLAGE ROAD, SUITE 149, SANTA BARBARA, CA., 93108, A CORP OF CA. (2)
4911917 Cholesterol-lowering combination comopsitions of magnesium salt and niacin 15 1988
4965252 Cholesterol-lowering combination compositions of guar gum and niacin 19 1988
 
Ortho-McNeil Pharmaceutical, Inc. (1)
4973468 Skin permeation enhancer compositions 100 1989
 
Mead Johnson & Company (1)
4465660 Sustained release tablet containing at least 95 percent theophylline 28 1982
 
TOSOH CORPORATION (1)
5178854 Cholesterol-lowering agents 10 1991
 
ZAMBON GROUP S.P.A. (1)
5196440 Compounds active as inhibitors of the cholesterol biosynthesis 15 1990
 
Neo-Bionics, Inc. (1)
4472436 Increasing HDL-cholesterol levels with phenylethylamine derivatives 8 1982
 
GLAXO GROUP LIMITED (1)
5278067 Cyclic ketal derivatives 6 1992
 
CHUGAI SEIYAKU KABUSHIKI KAISHA (1)
4454108 Prolonged-action multiple-layer tablets 27 1982
 
Smith Kline & French Laboratories Limited (2)
5169640 Pharmaceutical compositions 33 1989
5188839 Pharmaceutical compositions of cimetidine 20 1989
 
Union Carbide Corporation (1)
4946870 Delivery systems for pharmaceutical or therapeutic actives 153 1988
 
NOVARTIS CONSUMER HEALTH, INC. (1)
4752479 Multi vitamin and mineral dietary supplement with controlled release bioavailable iron 68 1986
 
SYNTHETIC BLOOD CORPORATION (1)
4963367 Drug delivery compositions and methods 275 1987
 
Sterling Drug Inc. (1)
4970081 Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith 20 1989
 
SHOWA DENKO K.K. (1)
4842863 Granular agent for ruminant and production method thereof 43 1988
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (6)
* 2006/0263,428 Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics 8 2006
* 2010/0076,033 Methods For Treating Hyperlipidemia with Intermediate Release Nicotinic Acid Compositions Having Unique Biopharmaceutical Characteristics 1 2009
* 2011/0245,300 NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR 0 2011
* 2012/0035,225 METHODS FOR TREATING HYPERLIPIDEMIA WITH INTERMEDIATE RELEASE NICOTINIC ACID COMPOSITIONS HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS 0 2011
* 2012/0245,207 NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR 0 2012
* 2013/0005,779 METHODS FOR TREATING HYPERLIPIDEMIA WITH INTERMEDIATE RELEASE NICOTINIC ACID COMPOSITIONS HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS 0 2012
 
PHARMENA SPOLKA AKCYJNA (PHARMENA S.A.) (8)
7935717 Method for treating hypertriglyceridemia, dyslipidemia and hypercholesterolemia with a 1-methylnicotinamide salt 2 2005
* 2008/0207,702 Use of Quaternary Pyridinium Salts as Vasoprotective Agents 4 2005
8124631 Use of quaternary pyridinium salts as vasoprotective agents 1 2010
* 2010/0173,956 Use of Quaternary Pyridinium Salts as Vasoprotective Agents 2 2010
8211922 1-methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities 0 2010
* 8481570 1-methylnicotinaide derivatives and formulations of treatment of lipoprotein abnormalities 0 2012
* 2012/0245,115 1-Methylnicotinaide Derivatives and Formulations of Treatment of Lipoprotein Abnormalities 0 2012
9119844 Use of quaternary pyridinium salts as vasoprotective agents 0 2014
 
Pharmena Spólka Akcyjna (Pharmena S.A.) (2)
8969391 Use quaternary pyridinium salts as vasoprotective agents 1 2011
9333196 Use of quaternary pyridinium salts as vasoprotective agents 0 2015
 
DR. REDDY'S LABORATORIES LIMITED (2)
* 2011/0123,575 MODIFIED RELEASE NIACIN FORMULATIONS 0 2009
* 2011/0086,074 COMBINATIONS OF NIACIN AND AN OXICAM 2 2009
 
NEXGEN PHARMA, INC. (1)
* 2007/0072,910 Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans 0 2005
 
KOS LIFE SCIENCES, INC. (2)
7998506 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 0 2003
* 2005/0118,257 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 7 2003
 
LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (1)
8658160 Composition and method for cancer chemoprevention 0 2007
* Cited By Examiner